comparemela.com

Latest Breaking News On - Cantargia - Page 1 : comparemela.com

Cantargia publishes ASCO 2023 poster on promising nadunolimab efficacy in non-small cell lung cancer

Cantargia today presented interim efficacy data for 39 non-small cell lung cancer patients treated with nadunolimab and platinum-based chemotherapy as a poster at the ASCO Annual Meeting 2023 , and. | June 4, 2023

Luis pazNon small cellCantargia ab publ stock exchangePress release023 canta se0006371126

Cantargia : The nomination committees statement

The nomination committee s proposal and reasoned statement to the annual general meeting in Cantargia on 23 May 2023 Background The. | April 24, 2023

Mikael wiberg alecta pensionsfMagnus perssonMats larssonFourth swedish national pension fundFirst swedish national pension fundMikael wibergAlecta pensionsfSwedish corporate governance codeCantargia ab publ stock exchangePress releaseAy canta se0006371126

Cantargia has submitted a phase I clinical trial application for its second project, CAN10

Cantargia today announced that an application has been submitted to start the phase I clinical trial for the IL1RAP-binding antibody CAN10, in development for treatment of systemic sclerosis and. | April 20, 2023

Cantargia ab publ stock exchangePress releaseClerosis canta se0006371126

Cantargia AB: Cantargia to host R&D Day on new clinical results of nadunolimab in pancreatic cancer on April 24, 2023

LUND, Sweden, April 4, 2023 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day focusing on new clinical results and biomarker data for

Region flamandeDavid libergVan cutsemDominique tersagoEric van cutsemPrnewswire cantargiaUniversity hospitals gasthuisbergVp researchUniversity of warsawBelgian foundationNasdaq stockholmDivision headDigestive oncologyEric vanMedical universityProf van cutsem

Cantargia AB: Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer

LUND, Sweden, March 14, 2023 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been

Dennis riedlPrnewswire cantargiaClinical research excluding trialsNasdaq stockholmClinical research excludingTherapeutic benefitMonday aprWednesday apr

vimarsana © 2020. All Rights Reserved.